pSivida Corp.  

(Public, NASDAQ:PSDV)   Watch this stock  
Find more results for PSDV
3.92
-0.02 (-0.51%)
Jan 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.83 - 3.93
52 week 3.26 - 5.09
Open 3.91
Vol / Avg. 110,352.00/84,863.00
Mkt cap 115.63M
P/E 12.12
Div/yield     -
EPS 0.32
Shares 29.35M
Beta 1.45
Inst. own 25%
Feb 9, 2015
pSivida Corp at Biotechnology Industry Organization CEO & Investor Conference - 3:30PM EST - Add to calendar
Dec 11, 2014
pSivida Corp Annual Shareholders Meeting
Dec 3, 2014
pSivida Corp at LD Micro Conference
Nov 7, 2014
Q1 2015 pSivida Corp Earnings Release
Nov 7, 2014
Q1 2015 pSivida Corp Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin 81.27% -384.54%
Operating margin 82.15% -388.43%
EBITD margin - -364.27%
Return on average assets 248.42% -68.63%
Return on average equity 325.24% -118.06%
Employees 24 -
CDP Score - -

Address

480 Pleasant St Ste B300
WATERTOWN, MA 02472-2463
United States - Map
+1-617-9265000 (Phone)
+1-617-9265050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

pSivida Corp. is a provider of miniaturized, sustained-release drug delivery products. The Company focuses on usage of Durasert and Tethadur drug delivery technologies to develop products that deliver drugs and biologics, while continuing to leverage these technologies through collaboration and license agreements. The Company focuses on treatment of chronic diseases of the back of the eye and is also exploring applications outside ophthalmology. Its lead product Medidur is in a pivotal Phase III clinical trial, licensed product ILUVIEN has been approved in the European Union and is pending approval with the United States Food and Drug Administration.

Officers and directors

David J. Mazzo Ph.D. Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Paul Ashton President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Leonard S. Ross Vice President - Finance, Principal Financial Officer
Age: 64
Bio & Compensation  - Reuters
Lori Freedman Vice President - Corporate Affairs, General Counsel, Company Secretary
Age: 47
Bio & Compensation  - Reuters
James J. Barry Ph.D. Director
Age: 55
Bio & Compensation  - Reuters
Douglas Evan Godshall Independent Director
Age: 49
Bio & Compensation  - Reuters
Michael W. Rogers Independent Director
Age: 54
Bio & Compensation  - Reuters
Peter G. Savas Independent Director
Age: 64
Bio & Compensation  - Reuters